hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
Equity Compensation Plan Information
The following table summarizes share and exercise price information for our equity compensation plans as of December 31, 2019.
(1) Includes 105,000 shares of our common stock issuable upon exercise of outstanding stock options and 340,000 shares issuable upon vesting of outstanding restricted stock units.
(2) Represents an individual option grant to our Chairman and Chief Executive Officer outside of, and prior to the establishment of, the 2013 Stock Incentive Plan in October 2013 referred to in the above table. The option agreement pertaining to such option grant contain customary anti-dilution provisions.
(3) Does not take into account outstanding restricted stock units as these awards have no exercise price.
Our 2013 Stock Incentive Plan (“2013 Plan”) provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock, (d) stock appreciation rights, and (e) other stock-based awards including restricted stock units. Awards under the 2013 Plan may be granted singly, in combination, or in tandem. Subject to standard anti-dilution adjustments as provided in the 2013 Plan, the 2013 Plan provides for an aggregate of 2,600,000 shares of our common stock to be available for distribution pursuant to the 2013 Plan. The Compensation Committee (or the Board of Directors) will generally have the authority to administer the 2013 Plan, determine participants who will be granted awards under the 2013 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2013 Plan may be granted to our employees, directors and consultants. As of December 31, 2019, there were options to purchase an aggregate of 605,000 shares of common stock outstanding and 340,000 shares issuable upon vesting of outstanding restricted stock units granted under the 2013 Plan, and a balance of 1,780,505 shares of common stock are reserved for issuance under the 2013 Plan.
Table:
 | Number of securities to be issued upon exercise of outstanding options and rights | Weighted-average exercise price of outstanding options and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column(a))
 | (a) | (b) | (c)
Equity compensation plans approved by security holders | 445,000(1) | $2.34(3) | 1,780,505
Equity compensation plans not approved by security holders | 500,000(2) | $1.19 | —
Total | 945,000 | $1.39(3) | 1,780,505


Question: What % of equity compensation plans that are approved are shares issuable upon vesting of outstanding restricted stock units?
Answer: 76.4
Calculation: 340,000/445,000
NOTE 23. EXPENSES BY NATURE
Research and development consists of the following:
The impairment expenses in 2018 and 2019 are related to customer specific projects.
The Company’s operations in the Netherlands, Belgium and the United States receive research and development grants and credits from various sources.
Table:
 | Year ended December 31, | 
 | 2018 | 2019
Research and development expenses | 125,280 | 150,745
Capitalization of development expenses | (49,688) | (60,202)
Amortization of capitalized development expenses | 12,039 | 15,597
Research and development grants and credits | (321) | (49)
Total research and development expenses | 87,310 | 106,091
Impairment of research and development related assets | 1,278 | 4,755
Total | 88,588 | 110,846


Question: Which year had the higher total research and development expense?
Answer: 2019
Calculation: For row 9, col3 to 4 find the larger number and the corresponding year in row 2
Sales and marketing expenses consist primarily of personnel expenses and costs associated with advertising, marketing events and trade shows.
Sales and marketing expenses decreased by $11.1 million during the year ended June 30, 2019 as compared to the prior fiscal year. This was primarily due to (i) a decrease in commissions expense of $6.6 million, of which approximately $8.9 million is the net result of the Company capitalizing more commission expense under Topic 606, whereas previously, under Topic 605, such costs would have been expensed as incurred, (ii) a decrease in marketing expenses of $5.7 million and (iii) a decrease in travel and communication expenses of $1.1 million. These were partially offset by (i) an increase in bad debt expense of $3.5 million as certain low dollar receivables were provided for entirely as they became aged greater than one year. Overall, our sales and marketing expenses, as a percentage of total revenues, decreased to approximately 18% from approximately 19% in the prior fiscal year.
Our sales and marketing labour resources increased by 103 employees, from 1,948 employees at June 30, 2018 to 2,051 employees at June 30, 2019.
Table:
increase (decrease) | Change between Fiscal increase (decrease) | 
(In thousands) | 2019 and 2018 | 2018 and 2017
Payroll and payroll-related benefits | $(48) | $48,717
Commissions | (6,588) | 16,993
Contract labour and consulting | (871) | 609
Share-based compensation | (752) | (454)
Travel and communication | (1,113) | 271
Marketing expenses | (5,742) | 3,880
Facilities | 808 | 8,373
Bad debt expense | 3,519 | 4,013
Other miscellaneous | (319) | 2,285
Total change in sales and marketing expenses | $(11,106) | $84,687


Question: What is the Total decrease in sales and marketing expenses from 2018 to 2019?
Answer: 11,106
GasLog Ltd. and its Subsidiaries
Notes to the consolidated financial statements (Continued)
For the years ended December 31, 2017, 2018 and 2019
(All amounts expressed in thousands of U.S. Dollars, except share and per share data)
7. Leases (Continued)
On February 24, 2016, GasLog’s subsidiary, GAS-twenty six Ltd., completed the sale and leaseback of the Methane Julia Louise with a subsidiary of Mitsui. Mitsui has the right to on-sell and lease back the vessel. The vessel was sold to Mitsui for a cash consideration of $217,000. GasLog leased back the vessel under a bareboat charter from Mitsui for a period of up to 20 years. GasLog has the option to repurchase the vessel on pre-agreed terms no earlier than the end of year ten and no later than the end of year 17 of the bareboat charter. The bareboat hire is fixed and GasLog had a holiday period for the first 210 days, which expired on September 21, 2016. This leaseback meets the definition of a finance lease under IAS 17 Leases.
The movements in right-of use assets are reported in the following table:
*The balance as of December 31, 2018 represented the vessel held under finance lease and was included in the financial statement line ‘‘Vessel held under finance lease’’, which was renamed to ‘‘Right-of-use assets’’ as of January 1, 2019.
Table:
Right-of-Use Assets | Vessel | Vessel Equipment | Properties | Other | Total
As of January 1, 2019 | 206,753(*) | 2,630 | 4,969 | 19 | 214,371
Additions | 1,001 | 336 | 1,080 | 47 | 2,464
Depreciation expense | (7,722) | (1,109) | (1,499) | (10) | (10,340)
As of December 31, 2019 | 200,032 | 1,857 | 4,550 | 56 | 206,495


Question: What was the change in properties from start to end 2019?
Answer: 419
Calculation: 4,969 - 4,550
Item 6. Selected Consolidated Financial Data
The following table presents selected consolidated financial data as of and for the five-year period ended December 31, 2019. Our past results of operations are not necessarily indicative of our future results of operations. The following selected consolidated financial data is qualified in its entirety by, and should be read in conjunction with, “Management's Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and the notes thereto included elsewhere herein.
Consolidated Balance Sheet Data:
Table:
 |  |  | As of December 31, |  | 
 | 2019 | 2018 | 2017 | 2016 | 2015
 |  |  | (In thousands) |  | 
Cash and cash equivalents | $19,505 | $18,017 | $22,553 | $26,838 | $35,128
Working capital | $1,116 | $6,356 | $7,646 | $14,643 | $16,046
Total assets | $54,538 | $43,424 | $45,672 | $53,530 | $68,579
Stockholders' equity | $10,863 | $14,059 | $13,078 | $18,064 | $21,387


Question: What is the change in the value of total assets between 2019 and 2018?
Answer: 11114
Calculation: 54,538-43,424
Contract Assets and Liabilities
The following table provides information about receivables, contract assets and contract liabilities from our revenue contracts with customers:
Contract assets include costs that are incremental to the acquisition of a contract. Incremental costs are those that result directly from obtaining a contract or costs that would not have been incurred if the contract had not been obtained, which primarily relate to sales commissions. These costs are deferred and amortized over the expected customer life.
We determined that the expected customer life is the expected period of benefit as the commission on the renewal contract is not commensurate with the commission on the initial contract. During the years ended December 31, 2019 and 2018, the Company recognized expense of $6.3 million and $2.9 million, respectively, related to deferred contract acquisition costs.
Contract liabilities include deferred revenues related to advanced payments for services and nonrefundable, upfront service activation and set-up fees, which under the new standard are generally deferred and amortized over the expected customer life as the option to renew without paying an upfront fee provides the customer with a material right. During the years ended December 31, 2019 and 2018, the Company deferred and recognized revenues of $397.5 million and $354.2 million, respectively.
A receivable is recognized in the period the Company provides goods or services when the Company’s right to consideration is unconditional. Payment terms on invoiced amounts are generally 30 to 60 days.
Table:
 | Year Ended December 31, | 
(In thousands) | 2019 | 2018
Accounts receivable, net | $120,016 | $133,136
Contract assets | 18,804 | 12,128
Contract liabilities | 50,974 | 52,966


Question: What was the deferred and recognized revenue in 2019?
Answer: $397.5 million
Option Exercises and Stock Vested in 2018
The following table sets forth the number of shares of common stock acquired during 2018 by our named executive officers upon the exercise of stock options or upon the vesting of RSUs or RSAs, as well as the value realized upon such equity award transactions.
(1) Calculated by multiplying (i) the fair market value of Class A common stock on the vesting date, which was determined using the closing price on the New York Stock Exchange of a share of Class A common stock on the date of vest, or if such day is a holiday, on the immediately preceding trading day less the option exercise price paid for such shares of common stock, by (ii) the number of shares of common stock acquired upon exercise.
(2) Reflects the aggregate number of shares of Class A common stock underlying RSUs and RSAs that vested in 2018. Of the amount shown for Messrs. Daswani and Murphy and Mses. Friar, Henry, Reses and Whiteley, 20,132, 6,741, 44,857, 59,014, 91,306 and 17,217 shares, respectively, of Class A common stock were withheld to cover tax withholding obligations upon vesting.
(3) Calculated by multiplying (i) the fair market value of Class A common stock on the vesting date, which was determined using the closing price on the New York Stock Exchange of a share of common stock on the date of vest, or if such day is a holiday, on the immediately preceding trading day, by (ii) the number of shares of common stock acquired upon vesting. Of the amount shown for Messrs. Daswani and Murphy and Mses. Friar, Henry, Reses and Whiteley, $1,389,704, $414,596, $2,782,628, $3,619,149, $5,502,076 and $1,114,287, respectively, represents the value of shares withheld to cover tax withholding obligations upon vesting.
Table:
 | Option Awards |  | Stock Awards | 
Name | Number of Shares Acquired on Exercise (#) | Number of Value Realized on Exercise ($)(1) | Shares Acquired on Vesting of RSUs and RSAs (#) (2) | Value Realized on Vesting of RSUs and RSAs ($) (3)
Mr. Dorsey | — | — | — | —
Ms. Friar | 1,082,343 | 54,631,297 | 95,889 | 5,788,657
Ms. Henry | 200,000 | 13,187,645 | 124,498 | 7,475,787
Ms. Reses | — | — | 189,577 | 11,284,454
Ms. Whiteley | 20,625 | 989,821 | 38,156 | 2,375,984
Mr. Daswani | — | — | 45,310 | 3,106,268
Mr. Murphy | — | — | 18,024 | 1,120,072


Question: What is the Number of Shares Acquired on Exercise for Ms Friar?
Answer: 1,082,343
entergy corporation and subsidiaries notes to financial statements this difference as a regulatory asset or liability on an ongoing basis , resulting in a zero net balance for the regulatory asset at the end of the lease term . the amount was a net regulatory liability of $ 61.6 million and $ 27.8 million as of december 31 , 2013 and 2012 , respectively . as of december 31 , 2013 , system energy had future minimum lease payments ( reflecting an implicit rate of 5.13% ( 5.13 % ) ) , which are recorded as long-term debt , as follows : amount ( in thousands ) .

Table:
 | amount ( in thousands )
2014 | $ 51637
2015 | 52253
2016 | 13750
2017 | 13750
2018 | 13750
years thereafter | 247500
total | 392640
less : amount representing interest | 295226
present value of net minimum lease payments | $ 97414
.

Question: what portion of the total future minimum lease payments represent the interest for system energy?
Answer: 75.2%
Calculation: divide(295226, 392640)
Life Sciences Segment
Selling, general and administrative: Selling, general and administrative expenses from our Life Sciences segment for the year ended December 31, 2019 decreased $5.0 million to $8.6 million from $13.6 million for the year ended December 31, 2018. The decrease was driven by comparably fewer expenses at the Pansend holding company, which incurred additional compensation expense in the prior period related to the performance of the segment. The decrease was also due to a reduction in costs associated with the sale of BeneVir in the second quarter of 2018.
Table:
Life Sciences Segment |  |  | 
 |  | Years Ended December 31, | 
 | 2019 | 2018 | Increase / (Decrease)
Selling, general and administrative | $8.6 | $13.6 | $(5.0)
Depreciation and amortization | 0.3 | 0.2 | 0.1
Loss from operations | (8.9) | $(13.8) | $4.9


Question: What was the Selling, general and administrative expenses from our Life Sciences segment for the year ended December 31, 2019?
Answer: $8.6 million
(1) For a description and reconciliation of non-GAAP financial measures presented in this document, please see the Non-GAAP Financial Measures page, or visit the Black Knight Investor Relations website at https://investor.blackknightinc.com.
(2) In 2019, the effect of our indirect investment in The Dun and Bradstreet Corporation was a reduction of Net earnings of $73.9 million primarily due to the effect of its purchase accounting adjustments, restructuring charges and other non-operating charges. In 2017, Net earnings includes a one-time, non-cash net tax benefit of $110.9 million related to the revaluation of our deferred income tax assets and liabilities as a result of the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”).
Table:
(in millions, except per share data) | 2019 | 2018 | 2017
Revenues | $1,177.2 | $1,114.0 | $1,051.6
Adjusted Revenues(1) | $1,177.7 | $1,116.5 | $1,056.1
Earnings before equity in losses of unconsolidated affiliates | $182.8 | $168.5 | $254.2
Net earnings(2) | $108.8 | $168.5 | $254.2
Net earnings margin | 9.2% | 15.1% | 24.2%
Net earnings attributable to Black Knight | $108.8 | $168.5 | $182.3
Net earnings attributable to Black Knight, per diluted share | $0.73 | $1.14 | $1.47
Adjusted Net Earnings(1) | $295.4 | $277.9 | $209.6
Adjusted EPS(1) | $1.99 | $1.87 | $1.38
Adjusted EBITDA(1) | $583.4 | $542.5 | $505.8
Adjusted EBITDA Margin(1) | 49.5% | 48.6% | 47.9%


Question: What were the net earnings in 2017?
Answer: 254.2
Year Ended December 31, 2019 Compared to Year Ended December 31, 2018
Revenues
Our Products and Licensing segment included revenues from sales of test and measurement systems, primarily representing sales of our Optical Backscatter Reflectometer, ODiSI, and Optical Vector Analyzer platforms, optical components and sub-assemblies and sales of our Hyperion and Terahertz sensing platforms. Our Products and Licensing segment revenues increased $22.5 million to $44.5 million for the year ended December 31, 2019 compared to $21.9 million for the year ended December 31, 2018.
The increase resulted primarily from $10.8 million of revenues realized from the legacy business of MOI and $10.5 million of revenues realized from the legacy business of GP during the year ended December 31, 2019. Continued growth in sales of our fiber-optic sensing products, including our ODiSI products directed toward the expanding use of composite materials and the need for improved means of testing their structural integrity, and our communications test instruments also contributed to this increase.
Our Technology Development segment revenues increased $5.1 million to $26.0 million for the year ended December 31, 2019 compared to $21.0 million for the year ended December 31, 2018. Revenues within this segment increased due to additional contract awards, including higher value Phase 2 SBIR contracts. The increase continues a growth trend experienced over the past two years largely driven by successes in Phase 2 SBIR awards. The increase was realized primarily in our intelligent systems, advanced materials, optical systems and terahertz research groups. As Phase 2 SBIR contracts generally have a performance period of a year or more, we currently expect Technology Development segment revenues to remain at a similar level for the near term.
Table:
 | Years ended December 31, |  |  | 
 | 2019 | 2018 | $ Difference  | % Difference
Products and licensing revenues | $44,491,041 | $21,949,689 | $22,541,352 | 102.7%
Technology development revenues | 26,024,674 | 20,967,556 | 5,057,118 | 24.1%
Total revenues | $70,515,715 | $42,917,245 | $27,598,470 | 64.3%


Question: What was the increase in the Products and Licensing segment revenue in 2019?
Answer: $22.5 million
Accrued expenses consisted of the following (in thousands):
Contract liabilities represent amounts that are collected in advance of the satisfaction of performance obligations under the new revenue recognition standard. See Recently Adopted Accounting Standards in Note 2 and Contract Liabilities in Note 6.
Table:
 | December 31, | December 31,
 | 2019 | 2018
Accrued payroll and related taxes | $3,985 | $3,800
Accrued federal, state, and local taxes | 2,635 | 1,827
Accrued bonus | 20,206 | 10,766
Self-insurance reserves | 2,238 | —
Employee stock purchase plan contributions | 4,716 | 6,473
Accrued sales commissions | 5,397 | 6,889
Accrued partner commissions | 7,043 | 5,535
Contract liabilities | 5,197 | —
Accrued purchase price related to acquisitions | 2,763 | —
Other | 7,924 | 6,811
Total | $62,104 | $42,101


Question: What are the total accrued expenses in 2018 and 2019 respectively?
Answer: 42,101, 62,104
Asset position of METRO AG
ASSETS
As of the closing date, METRO had total assets of €18,221 million, which are predominantly comprised of financial assets in the amount of €9,005 million, receivables from affiliated companies at €8,214 million and the usufructuary rights to the METRO and MAKRO brands which were recognised as an intangible asset (€883 million). Cash on hand, bank deposits and cheques amounted to €44 million. The financial assets predominantly consist of shares held in affiliated companies in the amount of €8,964 million which are essentially comprised of shares in the holding for wholesale companies (€6,693 million), in real estate companies (€1,278 million), in service providers (€470 million) and in other companies (€523 million). The financial assets account for 49.4% of the total assets. Receivables from affiliated companies amount to €8,214 million. This corresponds to 45.1% of the total assets. This position contains €6,117 million in receivables from a group-internal transfer of shares in affiliated companies at their carrying values and predominantly reflects the short-term financing requirements of the group companies as of the closing date.
Table:
€ million | 30/9/2018 | 30/9/2019
Non-current assets |  | 
Intangible assets | 1,001 | 939
Tangible assets | 2 | 3
Financial assets | 9.157 | 9,005
 | 10.160 | 9,947
Current assets |  | 
Receivables and other assets | 6,882 | 8,218
Cash on hand, bank deposits and cheques | 335 | 44
 | 7,217 | 8,262
Deferred income | 12 | 12
 | 17,389 | 18,221


Question: What was the percentage change in total assets in FY2019 from FY2018?
Answer: 4.78
Calculation: (18,221-17,389)/17,389
The following table reconciles the theoretical corporation tax expense to the reported tax expense using the UK corporation tax rate. The reconciling items represent the impact of rate differentials in tax jurisdictions and the impact of non-taxable benefits and non-deductible expenses arising from differences between the local tax base and the reported Financial Statements.
The Group’s taxation strategy is published at www.sophos.com/en-us/medialibrary/PDFs/legal/sophos-group-tax-poli
The Group’s taxation strategy is published at www.sophos.com/en-us/medialibrary/PDFs/legal/sophos-group-tax-policyfy19. pdf and is aligned to its business strategy and operational needs. Oversight of taxation is within the remit of the Audit and Risk Committee. The Chief Financial Officer is responsible for tax strategy supported by a global team of tax professionals. Sophos strives for an open and transparent relationship with all revenue authorities and is vigilant in ensuring that the Group complies with current tax legislation. The Group proactively seeks to agree arm’s length pricing with tax authorities to mitigate tax risks of significant cross-border operations. The Group actively engages with policy makers, tax administrators, industry bodies and international institutions to provide informed input on proposed tax measures, so that it and they can understand how those proposals would affect the Group. However, a tax authority may seek adjustment to the filing position adopted by a Group company and it is accepted that interpretation of complex regulations may lead to additional tax being assessed. Uncertain tax positions are monitored regularly and a provision made in the accounts where appropriate.
Table:
 | Year-ended 31 March 2019 | Year-ended 31 March 2018 Restated See note 2
 | $M | $M
Profit / (loss) for the year before taxation | 53.6 | (41.0)
Loss for the year before taxation multiplied by the standard rate of corporation tax in the UK of 19% (2018: 19%) | 10.2 | (7.7)
Effects of: |  | 
Adjustments in respect of previous years | 0.8 | 7.1
Change in tax rate during the year | 1.4 | 3.6
Expenses not deductible for tax purposes | 11.8 | 9.4
Losses not recognised | (0.9) | –
Higher tax rates on overseas earnings | 7.7 | 3.8
Research and development and other tax credits | (1.9) | (0.6)
Impact of US tax reform on deferred tax | – | 5.4
Other movements | (2.4) | (1.1)
Charge for taxation on profit / (loss) for the year | 26.7 | 19.9


Question: In which year was the Charge for taxation on profit  for the year larger?
Answer: 2019
Calculation: 26.7>19.9